University of Wisconsin, Madison psychedelic research trials
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
University of Wisconsin, Madison is listed with 10 registered studies counted here, in Madison, United States. By compound: 9 psilocybin and 1 ketamine. By registry status: 3 recruiting, 1 not yet recruiting, 3 completed, 1 terminated, 1 suspended and 1 withdrawn. By phase: 1 early phase 1 and 9 phase 1. Reported start years run from 2014 (earliest) to 2026 (latest).
Institution name, city and country are copied from the research site linked to each registry record. A study counts once per institution, and a study tagged with more than one compound is counted under each compound.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 10 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 9 |
| Ketamine | 1 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 3 | 30% |
| Not yet recruiting | 1 | 10% |
| Completed | 3 | 30% |
| Terminated | 1 | 10% |
| Suspended | 1 | 10% |
| Withdrawn | 1 | 10% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Early Phase 1 | 1 | 10% |
| Phase 1 | 9 | 90% |
Registered studies
All counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Compound |
|---|---|---|---|---|---|
| Ketamine-assisted Psychotherapy for Adolescent PTSD (KAP) | NCT06378528 | Suspended | Early Phase 1 | 2026-03-01 | Ketamine |
| Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study | NCT07360301 | Not yet recruiting | Phase 1 | 2026-02-01 | Psilocybin |
| The RECAP2 Study: Midazolam and Psilocybin | NCT06692192 | Recruiting | Phase 1 | 2025-08-07 | Psilocybin |
| The ENHANCE Study: taVNS and Psilocybin | NCT05866471 | Recruiting | Phase 1 | 2025-01-27 | Psilocybin |
| Consciousness, Psilocybin, and Well-Being | NCT05592379 | Completed | Phase 1 | 2023-11-07 | Psilocybin |
| Bioavailability Study of Psilocybin in Normal Adults | NCT05467761 | Withdrawn | Phase 1 | 2023-06-01 | Psilocybin |
| Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder | NCT05322954 | Terminated | Phase 1 | 2023-03-03 | Psilocybin |
| Pilot RECAP Study in Healthy Volunteers | NCT04842045 | Completed | Phase 1 | 2021-05-21 | Psilocybin |
| Adjunctive Effects of Psilocybin and a Formulation of Buprenorphine | NCT04161066 | Recruiting | Phase 1 | 2021-01-13 | Psilocybin |
| UW Psilocybin Pharmacokinetics Study | NCT02163707 | Completed | Phase 1 | 2014-06-01 | Psilocybin |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.